Quantcast
Last updated on April 19, 2014 at 8:29 EDT

Latest Cystic fibrosis Stories

2013-10-09 08:28:27

Application Brings Years of Work with Nitric Oxide Gas for Antimicrobial Use to Clinical Fruition GARDEN GROVE, Calif., Oct. 9, 2013 /PRNewswire/ -- Novoteris, LLC., a clinical stage medical device and pharmaceutical developer focused on innovative applications for nitric oxide gas where it can be applied for unmet medical needs, announced today that the Office of Orphan Products Development of the US Food and Drug Administration has granted it orphan drug designation for the use of...

2013-10-01 23:36:23

Best in Backyards will sponsor its local Boy Scout troop for the upcoming “Wrestle Cure,” a charitable event whose proceeds benefit Cystic Fibrosis. The event will take place on November 8th at 7 p.m. at the old High School in Mahopac N.Y. Mahopac, New York (PRWEB) October 01, 2013 Best in Backyards, New York and Connecticut’s leading provider of swing sets and other recreational backyard amenities, announces its sponsorship of Boy Scout Troop No. 1 for “Wrestle Cure.” The...

2013-09-27 23:25:28

Helping CF Patients Breathe Easier Claremont, CA (PRWEB) September 27, 2013 Synedgen announces the award of a National Heart Lung and Blood Institute (NHLBI) Small Business Innovation Research grant from the NIH to explore the mechanisms of a natural modified biopolymer to both reduce the viscosity of mucus and the cohesion of biofilms, potentially leading to a pulmonary treatment for patients with cystic fibrosis (CF) to enhance airway clearance and augment the activity of standard...

2013-09-24 08:31:14

Galapagos to host webcast presentation today at 15.00 CET/ 9 am ET/ 6 am PT NORTH CHICAGO, Ill. and MECHELEN, Belgium, Sept. 24, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today that they have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis (CF), an inherited chronic disease that affects 70,000 people worldwide. AbbVie and Galapagos will work collaboratively...

2013-09-18 16:26:21

Human Safety and PK/PD Data from Phase 1 Study of KB001 Supports Ongoing Phase 2 Clinical Trial of KB001-A in Cystic Fibrosis SOUTH SAN FRANCISCO, Calif., Sept. 18, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced the publication of Phase 1 study results for KB001, a first generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody, for use in patients with cystic fibrosis (CF). Data from this initial single dose clinical study...

2013-09-17 23:32:16

Advancements in Treatment and Research for Cystic Fibrosis (PRWEB) September 17, 2013 Causing severe damage to the lungs and the digestive system, Cystic Fibrosis is a life threatening disorder affecting nearly 30,000 children and adults in the U.S. Those inflicted with the disorder have an inherited defective gene which converts the mucus, typically a thin substance surrounding the tissues, into a thick and sticky substance. The thick mucus blocks the lungs, leading to lung infection and...

2013-09-16 16:25:21

ATLANTA, Sept. 16, 2013 /PRNewswire/ -- Atlanta-based pharmaceutical discovery and development company, Celtaxsys, Inc., announced today the achievement of a significant clinical milestone for its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis (CF) lung disease. Celtaxsys has successfully completed the first of two clinical trials in its Phase 1 program, and the first trial conducted through its Australia subsidiary, Celtaxsys Aus Pty Ltd. In this...

2013-09-11 23:20:17

ChanTest is a world leader in drug safety and discovery, in areas particularly relevant to Cystic Fibrosis. Cleveland, OH (PRWEB) September 11, 2013 The world is still looking for meaningful solutions to address the pain and suffering of patients with Cystic Fibrosis. On Thursday, September 12, ChanTest will be hosting a complimentary webinar entitled “Unfolding Cystic Fibrosis Research,” to share important information in this field. The event will include presentations by Dr....

2013-09-11 23:17:45

Mount Sinai is promoting the scientific discoveries of its faculty by facilitating the establishment and supporting incubator companies to accelerate the discovery of treatments for devastating diseases, including those that often affect relatively small populations. New York, NY (PRWEB) September 11, 2013 Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, has granted an exclusive license to Plexcera Therapeutics, LLC to commercially develop...

2013-09-10 12:29:37

Portable HFCWO airway clearance vest delivers dramatic improvements for respiratory patients, clinical study shows AUSTIN, Texas, Sept. 10, 2013 /PRNewswire/ -- AffloVest, the first-ever portable High Frequency Chest Wall Oscillation (HFCWO) vest, is now approved for Medicare and private health insurance reimbursement. Millions of Americans with respiratory disease can benefit from the innovative new airway clearance therapy vest that dramatically improves cough productivity and...


Latest Cystic fibrosis Reference Libraries

Cystic Fibrosis
2013-07-19 15:03:45

Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...

More Articles (1 articles) »